Company: ZURA
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-038042
Chunk: 53

Company: Zura Bio Ltd
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 53
---
 is the number of days between commencement of service as an eligible director and the date of such annual general meeting, and the denominator of which is 365. Each stock option described above will be granted under our 2023 Plan. The term of each stock option will be ten years from the grant date, subject to earlier termination as provided in the 2023 Plan, provided that upon a termination of continuous service other than for death or “cause” (as such term is defined in the 2023 Plan), the post-termination exercise period will be six (6) months from the date of termination. We will also reimburse each non-employee director for ordinary, necessary, and reasonable out-of-pocket travel expenses to cover in-person attendance at and participation in Board and committee meetings. 31

TABLE OF CONTENTS

EQUITY COMPENSATION PLAN INFORMATION The following table sets forth the aggregate information of our equity compensation plans in effect as of December 31, 2024.

| Plan Category                                          | ​ | ​ | Number of securities tobe issued upon exerciseof outstanding options,warrants and rights |   |               |   | ​ | ​ | Weighted-averageexercise price ofoutstanding options,warrants and rights($)(1) |   |      |   | ​ | ​ | Number of securitiesremaining available forfuture issuance underequity compensationplans (excludingsecurities reflectedin column (a)) |   |              |   | ​ |
| Equity compensation plans approved by shareholders     | ​ | ​ | ​                                                                                        | ​ | 13,469,665(2) | ​ | ​ | ​ | ​                                                                              | ​ | 2.88 | ​ | ​ | ​ | ​                                                                                                                                     | ​ | 1,863,283(3) | ​ | ​ |
| Equity compensation plans not approved by shareholders | ​ | ​ | ​                                                                                        | ​ |             — | ​ | ​ | ​ | ​                                                                              | ​ |    — | ​ | ​ | ​ | ​                                                                                                                                     | ​ |            — | ​ | ​ |
| Total                                                  | ​ | ​ | ​                                                                                        | ​ |    13,469,665 | ​ | ​ | ​ | ​                                                                              | ​ |    ​ | ​ | ​ | ​ | ​                                                                                                                                     | ​ |    1,863,283 | ​ | ​ |

(1) The weighted average exercise price relates only to stock options. The calculation of the weighted average exercise price does not include outstanding equity awards that are received or exercised for no